BLS

BLSPHARMA FPO [BLS]
BLS Pharmaceuticals Limited, together with its subsidiaries, manufactures and distributes therapeutic goods, and health and wellness products in Australia, the United States, the United Kingdom, Czech Republic, and Japan. The company offers medical cannabis, MDMA, psilocybin, prescription medicines, probiotics, NADs, and consumer health products under the Dr Watson and PCC brands. It also provides pharmaceutical manufacturing, wholesale, distribution, import, export, and contract drug manufacturing services for investigational and psychotropic medicines. The company caters to licensed clinics, pharmacies, wholesale distributors, cultivators, active pharmaceutical ingredient manufacturers, and pharmaceutical brand sponsors. The company was formerly known as Bioxyne Limited and changed its name to BLS Pharmaceuticals Limited in June 2026. BLS Pharmaceuticals Limited was incorporated in 1998 and is headquartered in Sydney, Australia.
Healthcare · ASX Small Cap
$0.8400 -5.6%

Updated 22 Jul 2026 · Signals refresh every scan

Appeared in 2 consecutive scansFirst seen: 2026-07-13
Get alerts when BLS triggers a new signal
Free watchlist with daily scans for 2,200+ ASX stocks
Track BLS — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is losing steam
  • Took a hit — down 11.1% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Trading above the 200-day average — the long-term trend is on your side
  • Cash positive / operating cashflow positive
  • Low P/S ratio (4.0x)
  • Strong revenue growth (+150%)
  • Piotroski F-Score strong (8/9, low-confidence approx)
  • Post-earnings drift: positive surprise (SUE +10)
  • Capital raise activity (1 events)
  • CANSLIM C: Strong EPS growth (124% QoQ)
  • CANSLIM S: Tight float (32%)
  • Strong return on equity (66%)
  • Healthy profit margins (19%)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 149% over the past year (excluding last month)
  • Excellent risk-adjusted returns — Sharpe of 1.5 means strong gains without wild swings
  • Earnings are trending the right way — 2 consecutive improvements
  • Revenue growing at +150% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (3.76%/day)
  • RBA hiking (-3pts)

Risk Signals

  • Not enough chatter to gauge sentiment — defaulting to neutral
Ask Scout AI about BLS
"What's driving BLS today?" "How does BLS compare to peers?" "Key risks for BLS?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE BLS Strengthens Gobal Psychedelic Medicines Platform
NONE Appendix 3H
NONE Appendix 2A
Announcement tone +5pts

Recent ASX Announcements

2026-07-20 BLS Strengthens Gobal Psychedelic Medicines Platform
2026-07-03 Appendix 3H
2026-07-03 Appendix 2A
2026-06-29 Change of Name - BLS Pharmaceuticals Limited
2026-06-19 Application for quotation of securities - BXN

Key Metrics

$193.2M
Market Cap
215K
Avg Volume
0.8x
Vol Ratio
$0.33 — $1.10
52-Week Range
0.0%
Short Interest
N/A
Cash Runway
66.1%
ROE
18.7%
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSpassEPS Growth: 124%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandpassFloat: 32%
LLeader vs LaggardpassRS: 22
IInstitutional SponsorshipweakInst: 1%
MMarket DirectionneutralNeutral

Sector: Healthcare

101 tickers in this sector

View all Healthcare signals →Browse all ASX tickers A–Z →
Related Tickers
IDT +28.1%ADR +27.3%LDX +23.8%EYE +17.4%ECS -16.7%
Compare:BLS vs IDTBLS vs ADRBLS vs LDX
Scout Pro — Deeper Analysis for BLS
Try Pro free for 30 days
Share this analysis

Track BLS and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and exit management for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required